Eps8, a bi-functional actin cytoskeleton remodeller, is a positive regulator of cell proliferation and motility. Here, we describe an unrecognized mechanism regulating Eps8 that is required for proper mitotic progression: whereas Eps8 is stable in G1 and S phase, its half-life drops sharply in G2. This requires G2-specific proteasomal degradation mediated by the ubiquitin E3 ligase SCF Fbxw5 . Consistent with a short window of degradation, Eps8 disappears from the cell cortex early in mitosis, but reappears at the midzone of dividing cells. Failure to reduce Eps8 levels in G2 prolongs its localization at the cell cortex and markedly delays cell rounding and prometaphase duration. However, during late stages of mitosis and cytokinesis, Eps8 capping activity is required to prevent membrane blebbing and cell-shape deformations. Our findings identify SCF Fbxw5 -driven fluctuation of Eps8 levels as an important mechanism that contributes to cell-shape changes during entry into-and exit from-mitosis.
Epidermal growth factor receptor pathway substrate 8 (Eps8) is a signalling adaptor that controls various cellular protrusions by regulating actin cytoskeleton dynamics and architecture [1] [2] [3] [4] . Depending on its association with other signal transducers, Eps8 can regulate the Rac GTPase (refs 5,6) or directly control actin dynamics by binding actin filaments and exerting either actin bundling or actin barbed-end capping activity 3, 4, 7 . Eps8 has been implicated in the regulation of processes such as axonal filopodia growth, stereocilia length, dendritic cell migration, cancer cell migration and invasion [8] [9] [10] [11] , and was shown to contribute to cell transformation in response to growth factor treatment 2 . Consistent with this, increased Eps8 levels have been linked to human tumour development and progression 9, [12] [13] [14] [15] [16] . Together, these findings indicate that Eps8 levels need to be tightly regulated. When overexpressed at high levels (for example, in some pancreatic cancers), Eps8 is subject to chaperone-mediated autophagy 17 , but whether regulated degradation contributes to normal Eps8 biology has so far remained elusive.
Regulated protein degradation is a key mechanism to control cellular processes. A major player in regulated degradation is the ubiquitin system, which marks proteins for proteasomal or lysosomal degradation 18 . Target specificity within the ubiquitin system is conferred by ubiquitin E3 ligases, which bind substrates and catalyse the transfer of ubiquitin from a ubiquitin E2 enzyme to a specific substrate 19 . Amongst several hundred E3 ligases, cullin-RING-based E3 ligases (CRLs) comprise the largest family. They are composed of a modular E3 core containing a cullin, a RING domain protein (Rbx1 or Rbx2), and a substrate specificity module usually composed of a linker protein and interchangeable substrate receptors 20 . Human cells express six closely related cullin proteins that nucleate different subfamilies of CRLs (CRL1-CRL5). In combination with dedicated substrate specificity modules these CRLs bind and ubiquitylate distinct sets of substrates 21 . The best-characterized subfamily of CRLs, Skp1-Cul1-F-box (SCF) complexes, uses interchangeable F-box proteins as substrate receptors 22, 23 . Here, we demonstrate that Eps8 is subject to regulated degradation specifically in the G2 phase of the cell cycle. This requires the E3 ligase SCF Fbxw5 and proteasomal degradation. Failure to transiently degrade Eps8 before mitosis results in prolonged presence of Eps8 at the cell cortex, a delay in cell rounding and prolonged prometaphase duration. On the other hand, insufficient Eps8 capping activity during anaphase and telophase induces membrane blebbing and cell shape deformations. Together, these findings implicate SCF Fbxw5 -mediated regulation of Eps8 levels as a crucial mechanism to regulate cell-shape changes required for mitotic progression. Anti-Eps8
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RESULTS

Eps8 is an interaction partner of the F-box protein Fbxw5
During a project aimed at identifying binding partners for the F-box protein Fbxw5, a substrate receptor of SCF-type ubiquitin E3 ligases 24, 25 , we identified Eps8 peptides in an immunoprecipitation/mass spectrometry-based screen ( Supplementary Fig. S1a,b) . We verified the Fbxw5-Eps8 interaction both with anti-Flag immunoprecipitates from HEK293T cells stably expressing flag-Fbxw5 ( Supplementary Fig. S1c ), and with anti-Fbxw5 immunoprecipitates (using affinity-purified polyclonal antibodies) from untransfected cells ( Supplementary Fig. S1d ). To exclude that the observed interaction is mediated by Skp1, Cul1 or Rbx1, we repeated the anti-Flag immunoprecipitation on transfection of an Fbxw5 derivative (flag-Fbxw5 F-box) that cannot be integrated into SCF complexes. The interaction between Eps8 and Fbxw5 remained unchanged ( Supplementary Fig. S1e ), suggesting that it may reflect a bona fide E3 ligase-substrate interaction. These findings inspired us to follow up on a possible regulation of Eps8 by the ubiquitin/proteasome system.
Eps8 is subject to Fbxw5-dependent proteasomal degradation during G2 phase of the cell cycle
Initial experiments with asynchronous cells indicated that Eps8 is a stable protein (see below). However, targets for SCF E3 ligases are frequently degraded at a specific time in the cell cycle. To explore this possibility, we compared cycling versus S-phase-(aphidicolin, thymidine or hydroxyurea) or G2/M-phase-(nocodazole, taxol or S-trityl-l-cysteine (STLC)) arrested HeLa cells. Indeed, immunoblotting revealed a striking reduction of Eps8 levels in G2/M-arrested cells (Fig. 1a) . To determine whether this reduction is also observed during normal cellcycle progression, we synchronized HeLa cells using a double thymidine block/release protocol (Fig. 1b) RanGAP1 not yet phosphorylated) and reached S-phase levels again at the 12 h time point (predominantly G1 phase). Eps8 levels inversely correlated with cyclin B1 levels, and minimal Eps8 levels were observed Fbxw5 reconstitution, mouse Fbxw5/Skp1 complexes were purified from bacteria (see Methods) and Cul1/Rbx1 complexes were purified from Escherichia coli using a split and co-express approach and in vitro neddylated as previously described 31, 32 . when RanGAP1 phosphorylation was maximal (8.5-9 h release). Hence, we concluded that Eps8 is a cell-cycle-regulated protein.
To investigate whether fluctuating Eps8 levels are due to regulated degradation, we treated synchronized HeLa cells 2, 6 or 7 h after thymidine release with cycloheximide. Whereas Eps8 levels were stable in S phase (2 h after thymidine release), they rapidly decreased in cells that had been released from thymidine for 6 or 7 h (Fig. 1c) . This reduction of Eps8 half-life to approximately 45 min indicates that Eps8 is significantly reduced but not completely degraded during G2 and M phase. Consistent with G2-specific Eps8 regulation, treatment of HeLa cells with MG132 for 3 h increased Eps8 levels in G2 cells (released from thymidine-arrest for 5 h), but not in unsynchronized cells (Fig. 1d) . Thus, Eps8 undergoes specific degradation by the ubiquitin/proteasome pathway during G2. To address whether Fbxw5 contributes to G2-specific degradation of Eps8, we treated HeLa cells with Fbxw5 short interfering RNA (siRNA) for 24 h, added taxol for 18 h, and investigated Eps8 levels by immunoblotting. Whereas depletion of Fbxw5 for 42 h had no visible effect on asynchronous cells ( Fig. 1e and Supplementary  Fig. S2a ), it efficiently blocked Eps8 degradation in taxol-arrested cells. Thus, Fbxw5 is required for Eps8 degradation in G2.
Eps8 is a substrate for SCF Fbxw5 -dependent ubiquitylation
To determine whether Eps8 is a target for Fbxw5-dependent ubiquitylation, we subjected purified His-Eps8 to in vitro ubiquitylation assays. First, we used mammalian Fbxw5 complexes as a source of E3 ligases. Increasing amounts of flag-Fbxw5 immunoprecipitate fractions (Fig. 2a , lanes 5 and 6) induced Eps8 ubiquitylation, whereas control immunoprecipitate fractions from mock-transfected cells did not (Fig. 2a, lanes 7-8) . Although the most likely interpretation of these findings was that Eps8 is ubiquitylated by SCF Fbxw5 E3 ligase complexes, previous studies had suggested that Fbxw5 functions not only in the context of SCF complexes 24 , but also in the context of CRL4 complexes 29, 30 . To determine which of these E3 ligases mediates Eps8 ubiquitylation, we included flag-Fbxw5 F-box in our analyses. This Fbxw5 variant is deficient in binding of Skp1, the linker of SCF E3s, but is still capable of binding DDB1, the linker of CRL4 E3s ( Supplementary  Fig. S3a,b) . As shown in Fig. 2a (lanes 9 and 10) , flag-Fbxw5 F-box immunoprecipitates showed no activity, indicating that Fbxw5 requires the SCF core for its activity towards Eps8.
To exclude the contribution of other proteins that might coimmunoprecipitate with flag-Fbxw5, we reconstituted SCF Fbxw5 complexes. For this, we used an approach described for SCF Skp2 and SCF βTRCP1 ( Fig. 2b; refs 31,32) . First, we produced in vitro neddylated Cul1/Rbx1 (Nedd8 * Cul1/Rbx1) complexes using proteins obtained exclusively from bacterial expression. For SCF complex formation, we mixed Nedd8 * Cul1/Rbx1 in equimolar amounts with Fbxw5/Skp1 complexes, which we had separately purified from bacteria. These recombinant SCF Fbxw5 complexes efficiently stimulated ubiquitylation of His-Eps8 (Fig. 2c) , either in the presence of UbcH5b or Cdc34 (Fig. 2d) , two E2 enzymes known to work with SCF complexes 33, 34 . In conclusion, SCF Fbxw5 complexes are necessary and sufficient to ubiquitylate Eps8 in vitro.
Fbxw5 contributes to timely displacement of Eps8 from the cell cortex at the onset of mitosis
To add information on Eps8 localization, we turned to U2OS cells; these cells express more Eps8 than HeLa cells and allow detection of endogenous Eps8 by immunofluorescence analysis. After confirmation that Eps8 is subject to cell-cycle-dependent degradation also in these cells (Fig. 3a, anti-Eps8 immunoblotting ± taxol treatment), we analysed the localization of endogenous Eps8 in asynchronously growing U2OS cells. Consistent with previous studies 3, 35 , Eps8 was enriched at the cell cortex in most interphase cells (Fig. 3b) . Strikingly however, we found that more than 50% of prophase cells and more than 70% of prometaphase cells showed no prominent cell cortex association of Eps8 (Fig. 3c) , revealing that-concomitant with its Fbxw5-mediated degradation at G2/M (Figs 1 and 3a) -Eps8 displaces from the cell cortex at the onset of mitosis. Hence, it was conceivable that Fbxw5 contributes to the removal of Eps8 from the cell cortex. To test this hypothesis, we analysed prometaphase cells of a mock-transfected and Fbxw5-depleted U2OS cell population by immunofluorescence microscopy. As shown in Fig. 3d (representative images) and Fig. 3e (quantification) , depletion of Fbxw5 resulted in almost twice as many prometaphase cells exhibiting Eps8 at the cell cortex when compared with the control. Thus, Fbxw5-mediated degradation contributes to timely displacement of Eps8 from the cell cortex during the onset of mitosis.
SCF
Fbxw5 -mediated Eps8 degradation in G2 is required for timely progression into metaphase
To begin to address whether SCF Fbxw5 -dependent Eps8 degradation contributes to mitotic progression, and to test for possible changes in tubulin and actin organization, we transfected two different stable HeLa cell lines expressing either α-tubulin-GFP and H2B-RFP (ref. 36) or LifeAct-GFP and H2B-RFP (ref. 37) with non-targeting siRNA or siRNA targeting Fbxw5 and monitored cells undergoing mitosis using time-lapse fluorescence microscopy. Bipolar spindle formation (α-tubulin-GFP cells) and overall actin distribution (LifeAct-GFP cells) appeared normal at this level of resolution ( Supplementary  Fig. S4a and Supplementary Videos S1-S3). However, both cell lines exerted a striking delay in prometaphase following Fbxw5 depletion ( Supplementary Fig. S4b-c and Videos S3). Consistent with this, regular HeLa populations fixed 72 h after treatment with Fbxw5 siRNA showed a significant accumulation of prometaphase cells when compared with control populations (Fig. 4a; corresponding Eps8 levels ± siRNA are shown in Fig. 4b and Supplementary Fig. S2b ). Quantification revealed an increase in the percentage of cells in proand prometaphase from 19% in control to 63% in Fbxw5-depleted cells (Fig. 4c) . This was accompanied by a decrease in the percentage of cells in metaphase (from 39 to 9%) and ana-/telophase (from 43% in control to 28% in Fbxw5-depleted cells). Of note, the overall mitotic index of wild-type and Fbxw5-depleted HeLa cells remained the same ( Supplementary Fig. S5a,b) .
These findings suggested that Eps8 degradation is required for timely progression through prometaphase. However, E3 ligases frequently have many targets, and Fbxw5 is known to mediate degradation of the tumour suppressor TSC2 (ref. 29 ) and the centriolar protein SAS-6 (ref. 24 ). SAS-6 is required for centrosome duplication 38 , and both GFP-SAS-6 overexpression 38 and siRNA-mediated Fbxw5 depletion 24 cause centrosome overduplication and an increase in the number of mitotic cells with multipolar spindles, which could cause a prometaphase delay. However, most cells had bipolar spindles. Consistent with this, we observed only few cells with multipolar spindles on Fbxw5 siRNA knockdown for 48 or 72 h, and excluded them from our analyses. We employed two independent approaches to examine whether Eps8 regulation is involved in prometaphase progression: first, rescue of the Fbxw5-depletioninduced prometaphase delay by co-depletion of Eps8 (Fig. 4b,c) and second, investigation of mitotic stage distribution on ectopic expression of GFP-Eps8 (Fig. 4d,e) . As shown in Fig. 4b , simultaneous depletion of Fbxw5 and Eps8 resulted in Eps8 levels slightly above those of control cells (siRNA against Eps8 alone caused partial depletion, down to approximately 30%). Importantly, this reduction in Eps8 levels could restore a normal distribution of mitotic phases (Fig. 4c) , whereas reduction of the Eps8 level alone had no effect. Moreover, ectopic expression of GFP-Eps8 (but not of GFP) was sufficient to significantly increase the percentage of mitotic cells in prometaphase (Fig. 4d,e) . Taken together, these data demonstrate that indeed Eps8 needs to be degraded by SCF Fbxw5 for timely transition through prometaphase.
Failure to degrade Eps8 leads to a delay in cell rounding in early mitosis
The actin cytoskeleton undergoes marked changes to allow for cellshape changes required for proper transition into and out of mitosis 39 . Recently, the actin crosslinking protein moesin 40 and the RhoGEF Ect2 (ref. 37) were identified as crucial regulators of mitotic cell rounding. Considering that Eps8 functions as an actin capper in interphase 3 , we reasoned that increased Eps8 levels during early mitosis may interfere with cell rounding (live-cell analysis provided the first hints, but was not conclusive at our level of resolution). To test this idea, we transfected U2OS cells with different combinations of control, Fbxw5 and Eps8 siRNAs. As in HeLa cells (Fig. 4b) , Eps8 siRNA treatment decreased-and Fbxw5 siRNA treatment increased-steady state levels of Eps8 72 h after transfection (Fig. 5a) . Analysis of fixed cells stained with phalloidin and Hoechst revealed a striking accumulation of flat or only partially rounded prometaphase cells in Fbxw5-depleted when compared with control populations (Fig. 5b) : rounded prometaphase cells dropped from 86% in control to 42% in Fbxw5-knockdown populations, whereas partially rounded (and flat) prometaphase cells increased from 8% (6%) in control to 23% (35%) in Fbxw5-depleted populations (Fig. 5c) . Importantly, whereas removal of Eps8 alone had little effect, co-depletion of Fbxw5 and Eps8 partially rescued the cell-rounding defect (Fig. 5c) . Together, these findings reveal that Fbxw5-mediated degradation of Eps8 at the onset of mitosis contributes to timely cell rounding.
Capping activity of Eps8 is required for proper exit from mitosis
As shown in Fig. 1b , Eps8 levels are restored once cyclin B levels are again low (12 h after release from a double thymidine block). Consistent with this, a recent report revealed that Fbxw5 is inactivated by APC/C-mediated proteasomal degradation during mitosis 24 . We thus wondered when Eps8 would be needed again at the cell cortex-after metaphase/anaphase transition or only following completion of M phase. When analysing the localization of endogenous Eps8 in U2OS cells, we could detect prominent enrichment of Eps8 at the equatorial cortex in anaphase and telophase (Fig. 6a) . To test whether this pool plays a functional role in mitotic exit, we analysed mitotic HeLa cells transfected with different combinations of non-targeting, Fbxw5 and Eps8 siRNAs by live-cell imaging using differential interference contrast (DIC) microscopy. This revealed a striking blebbing phenotype: as has been observed by many laboratories (for example, refs 41,42), control cells exhibited weak or intermediate membrane blebbing during progression through ana-and telophase and both developing daughter cells exhibited a round shape at all times ( Fig. 6b and Supplementary Videos S1). The same was true for Fbxw5-depleted cells. In contrast, Eps8-depleted cells frequently exhibited pronounced membrane blebbing and massive cell deformations after metaphase until completion of mitosis (61%, 39 out of 64 cells). The blebbing phenotype could be rescued by co-depletion of Fbxw5, indicating that it is indeed caused by lack of Eps8 (as shown in Fig. 4a , Eps8 knockdown is partial in HeLa cells and Eps8 levels close to those of the control can be restored in the double knockdown). To verify these findings by an independent approach, we monitored mitotic Eps8-null mouse embryonic fibroblasts (MEF Eps8 −/− ) infected with control viruses or viruses encoding GFP-Eps8, a capping-deficient mutant of Eps8 (GFP-Eps8 Cap; ref. 7) , or a bundling-deficient mutant of Eps8 (GFP-Eps8 Bund; ref. 7) by time-lapse DIC microscopy ( Fig. 7a-c) . Indeed, 39% (28 of 72) of control-infected MEFs exhibited strong blebbing and cell deformation during exit of mitosis, whereas only 17% of Eps8-infected MEFs showed a comparable phenotype (Fig. 7b) . Consistent with this, only 28% of control-infected MEFs but 46% of Eps8-expressing MEFs showed no recognizable sign of blebbing. Importantly, whereas the bundling mutant of Eps8 also rescued the blebbing phenotype of MEF Eps8 −/− cells, re-expression of GFP-Eps8 Cap even aggravated blebbing and cell deformations during late mitosis. Together, these findings reveal that capping activity of Eps8 is required after metaphase for proper exit from mitosis.
DISCUSSION
SCF E3 ligases have been implicated in diverse aspects of cell-cycle regulation, for example through the F-box proteins Fbxw7, Skp2, β-TRCP and cyclin F (refs 43,44) . Here, we show that SCF Fbxw5 contributes to mitotic progression by regulating the actin-binding protein Eps8. In combination with the recently described role of SCF Fbxw5 in centrosome duplication during S phase 24, 25 , our findings identify Fbxw5 as an important player in cell-cycle control. An intriguing question is how recognition of Eps8 specifically in G2 is controlled: whereas recognition by prototypic SCF E3 ligases typically requires target phosphorylation [45] [46] [47] [48] [49] [50] [51] , both mock-or CIP-treated Eps8 from SF9 cells ( Supplementary Fig. S6a,b) are efficiently ubiquitylated by SCF Fbxw5 in vitro. Thus, Fbxw5 has no absolute requirement for target phosphorylation. Whether Eps8 has a degron that can be regulated by stimulatory or inhibitory modifications in vivo remains to be seen. Target recognition could also be regulated at the level of the E3 ligase 52 . However, SCF Fbxw5 complexes efficiently ubiquitylate Eps8 in vitro, irrespective of whether they are immunopurified from mammalian cells or reconstituted from bacterially expressed proteins ( Fig. 2 and Supplementary Fig. S6a,b ). An inhibitory phosphorylation has been described for Fbxw5, Plk4-dependent phosphorylation of Ser 151, in the context of Sas-6 degradation 24 . However, SCF Fbxw5 variants with S151A or S151D showed no differences when compared to wild-type SCF Fbxw5 in binding or ubiquitylation of Eps8 ( Supplementary Fig. S6c,d) cortical Eps8 may be released from-or SCF Fbxw5 may be recruited to-the cortex specifically in G2. It is interesting to note that a fraction of Fbxw5 undergoes a mobility shift at that time (Fig. 1b) and we will follow up on this in the future.
Eps8 controls actin-based protrusion events such as axonal filopodia growth, stereocilia length and cell migration by either capping or crosslinking actin filaments 3, 4, 7, 8, 53 . Here, we discovered a so far unrecognized role for Eps8 in mitosis: it is required for cell-shape stability late in mitosis and cytokinesis. On the other hand, cortical Eps8 inhibits timely cell rounding at the onset of mitosis, and its levels need to be temporally reduced by SCF Fbxw5 -dependent degradation in G2. These findings are intriguing in light of the emerging importance of actin cortex dynamics throughout M phase (for example, for centrosome separation, spindle positioning, cytokinesis) 37,39,42,54,55 .
In interphase cells, lammellipodia are composed of highly branched and short actin filaments (a situation that requires elevated levels of capping proteins 56, 57 ), whereas mitotic cells are characterized by long actomyosin-positive filaments under high tension 39, 40 . Recently, moesin, a member of the ERM (erzin, radixin, moesin) family of actin-binding proteins 40 and the RacGEF Ect2 (ref. 37 ) were identified as key players in driving cell rounding and spindle assembly through establishment of a stiff, rounded metaphase cortex. Given that under conditions of reduced Eps8 capping activity the actin network can become sparser 10 and presumably less stiff, we speculate that displacement of Eps8 from the cortex at the onset of mitosis favours changes in actin network architecture to facilitate ERM-and Ect2-driven cell rounding and cortex stiffening. Consistent with this, Fbxw5-depleted (Fig. 5) , moesin-depleted 40 and Ect2-depleted 37 cells exhibit similar defects in cell rounding at the onset of mitosis. After metaphase-anaphase transition, insufficient Eps8 capping activity causes pronounced membrane blebbing and cell-shape deformations (Figs 6b and 7 ). Given the recently described roles of membrane blebs and actomyosin contractility in cytokinesis 42 , these observations suggest that Eps8 is required for the establishment of an actin-rich furrow and the generation of a branched actin network to fill blebs. Collectively, our data are consistent with the following model ( Fig. 8) : SCF Fbxw5 -mediated degradation contributes to displacement of Eps8 from the cell cortex in late G2 to facilitate cell rounding and establishment of an ERM-linked actomyosin contractile cortex network in metaphase; before or at the onset of anaphase, SCF Fbxw5 is inactivated by APC/C Cdc20 -mediated degradation 24 ; this prevents further degradation of Eps8 and allows enrichment of newly synthesized and/or residual Eps8 at the equatorial cortex, which in turn contributes to changes in the actin cortex architecture favouring proper completion of mitosis. How Eps8, ERM proteins and Ect2 cooperate in regulating mitotic cell shape changes will thus be an important field for future studies. An intriguing question that arises from our study is also whether the contribution of aberrant Eps8 levels to tumour development 9, [12] [13] [14] [15] [16] is mediated-at least in part-by improperly executed mitosis.
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